Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07329640
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
PF-07329640 is a tetravalent monoclonal antibody developed by Pfizer as an agonist of the lymphotoxin beta receptor (LTβR, also known as TNFRSF3). The drug was designed to activate LTβR signaling, with the aim of inducing tertiary lymphoid structure formation and maturation in solid tumors—a novel immunotherapeutic approach. It was investigated primarily for advanced or metastatic solid tumors, including melanoma, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and urothelial carcinoma. The agent was tested both as monotherapy and in combination with bevacizumab or sasanlimab. Clinical development reached phase 1/2 trials but was terminated after limited enrollment due to strategic business decisions[2][5][6].
- Other names
- alphaLTbetaR
02
Targets
TNFR (TNF receptor family)
Beyond the preview
Go deeper on PF-07329640.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07329640.